Aurinia Pharmaceuticals
AUPH
200 hedge funds and large institutions have $487M invested in Aurinia Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 65 increasing their positions, 50 reducing their positions, and 18 closing their positions.
83% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 18
30% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 50
8% more funds holding
Funds holding: 186 → 200 (+14)
8% more call options, than puts
Call options by funds: $22.5M | Put options by funds: $20.8M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.24% less ownership
Funds ownership: 35.43% → 35.19% (-0.24%)
12% less capital invested
Capital invested by funds: $553M → $487M (-$66M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$7.83M |
| 2 |
Two Sigma Investments
New York
|
+$6.69M |
| 3 |
TAL
TIG Advisors LLC
New York
|
+$5.82M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$5.73M |
| 5 |
AC
Armistice Capital
New York
|
+$5.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.5M |
| 3 |
N
Natixis
Paris,
France
|
-$10M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.26M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.71M |
AUPH Hedge Fund Activity: Q2 2023 in Review
200 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2023, worth a combined $487M — down 12% from $553M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AUPH positions and 18 closed out — a net gain of 15 holders — while 65 added to existing stakes and 50 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $7.83M. The largest seller was Citadel Advisors, cutting an estimated $21.6M.
- 200 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2023, up from 186 in Q1 2023.
- Funds reported $487M of Aurinia Pharmaceuticals stock for Q2 2023, down 12% quarter-over-quarter.
- 33 funds opened new Aurinia Pharmaceuticals positions in Q2 2023 and 18 closed out, a net change of +15 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2023 was Goldman Sachs, an estimated $7.83M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2023 was Citadel Advisors, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2023.